Jeet Mukherjee
Stock Analyst at BTIG
(4.38)
# 325
Out of 5,163 analysts
37
Total ratings
64.86%
Success rate
15.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Assumes: Buy | $19 | $5.60 | +239.29% | 1 | Mar 12, 2026 | |
| IPHA Innate Pharma | Assumes: Buy | $8 | $1.50 | +433.33% | 1 | Mar 12, 2026 | |
| IBRX ImmunityBio | Assumes: Buy | $13 | $8.39 | +54.95% | 1 | Mar 12, 2026 | |
| AAPG Ascentage Pharma Group International | Assumes: Buy | $48 | $24.43 | +96.48% | 1 | Mar 12, 2026 | |
| AVBP ArriVent BioPharma | Assumes: Buy | $42 | $23.90 | +75.73% | 1 | Mar 12, 2026 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $9 | $5.09 | +76.82% | 3 | Mar 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $138 → $134 | $79.03 | +69.56% | 6 | Feb 26, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $192 → $215 | $122.06 | +76.14% | 5 | Feb 25, 2026 | |
| MNPR Monopar Therapeutics | Reiterates: Buy | $104 | $60.36 | +72.30% | 6 | Feb 23, 2026 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $30 | $15.04 | +99.47% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.00 | +180.00% | 3 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $19.19 | +45.91% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.90 | +124.49% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $14 | $12.18 | +14.94% | 2 | Oct 30, 2025 |
Verastem
Mar 12, 2026
Assumes: Buy
Price Target: $19
Current: $5.60
Upside: +239.29%
Innate Pharma
Mar 12, 2026
Assumes: Buy
Price Target: $8
Current: $1.50
Upside: +433.33%
ImmunityBio
Mar 12, 2026
Assumes: Buy
Price Target: $13
Current: $8.39
Upside: +54.95%
Ascentage Pharma Group International
Mar 12, 2026
Assumes: Buy
Price Target: $48
Current: $24.43
Upside: +96.48%
ArriVent BioPharma
Mar 12, 2026
Assumes: Buy
Price Target: $42
Current: $23.90
Upside: +75.73%
Aardvark Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $26 → $9
Current: $5.09
Upside: +76.82%
Kymera Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $138 → $134
Current: $79.03
Upside: +69.56%
Palvella Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $192 → $215
Current: $122.06
Upside: +76.14%
Monopar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $104
Current: $60.36
Upside: +72.30%
Nurix Therapeutics
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $15.04
Upside: +99.47%
Jan 13, 2026
Reiterates: Buy
Price Target: $14
Current: $5.00
Upside: +180.00%
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $19.19
Upside: +45.91%
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $4.90
Upside: +124.49%
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $12.18
Upside: +14.94%